|
Post by joeypotsandpans on May 23, 2018 12:53:00 GMT -5
The above coming from the gentleman who just earlier today posted that if the bionic pancreas system works, it will clean up in he T1 market. You believe this would be cheaper than $5k per year? Regarding CGM’s, I believe the Libre Freestyle is not much over $1k per year to operate. I think it would cost more than $5k per year, but that would not be an issue. Right now CGMs are relatively easy to get if you are a Type 1 with insurance, however they are only 10% of the Type 1 market (pretty much 0% of the Type 2 market) because they are not compelling. If you are hypo-unaware they are a lifesaver, and CGMs improve your A1c, and significantly reduce your hypos (by about 25% I think) so there is a definite incentive, but with only 10% uptake obviously not enough of an incentive. So why would the bionic pancreas clean up and the CGM hasn't? With a CGM I actually spend more time. not less, dealing with diabetes because instead of only checking at meal times I am looking in between (am I up, am I down, where did that spike come from, all these questions I have now). With an AP it's just sitting there humming away and I can ignore it - that is compelling and this is coming from someone who avoids pumps. The Libre is subsidized at the moment as Abbott are inserting a coupon into the prescription process to keep the price to $75. When they stop the price will double based on the original price. Still cheaper than a CGM even then though if you are self-funding. Just an FYI, when I picked up my libre this week at CVS I was pleasantly surprised when they said "that will be $40"....I couldn't get my debit card in the pullout bin fast enough lol not sure what happened since last month but that was sweet to hear. Loving this new VGK themed font color so you will probably have to bear with it for a couple of weeks
|
|
|
Post by joeypotsandpans on May 23, 2018 12:45:30 GMT -5
Winner of tonights game will take the series. If the rustbelt team wins tonight, they will close it out game 6. If they don't win, it will be Celts on to the finals in 7. Sorry, Scotta, Joey and I were talking real sports! Celtics? Yes sir!! VGK will be up to the challenge with either team but it sure would be nice to have home ice and not have to travel east for the first two
|
|
|
Post by joeypotsandpans on May 23, 2018 12:38:39 GMT -5
Medicare yes, but I don't think that is yet true for other insurance for T2s. It should be for all patients needing insulin. The Advantage plans are bit spotty - I *think* Kaiser is the only one that will let you have a CGM at the moment. If you are direct with Medicare then there is a lot less of a problem. Medicare has selection criteria to decide if you get a CGM. At the restaurant Mike mentioned he has been in talks with Kaiser towards their better involvement in working with Afrezza...your post reminded me of that part of his conversation with us.
|
|
|
Post by joeypotsandpans on May 22, 2018 15:25:51 GMT -5
DBC,look at it this way if one is worried about the length of the runway then they shouldn't be on the aircraft, correct? It's all about choices and those making the choice to invest in entry level biotechs should know or be aware of the dilution cycles that come with them, it's generally speaking their only source of fuel to get off the runway . So either most of those on board are confident in the current personnel in the cockpit and the aircraft their on or they're nervous stowaways that are on board for other reasons
|
|
|
Post by joeypotsandpans on May 22, 2018 15:05:16 GMT -5
I did. I read every post. My comment above was not about STAT but rather the late-breaking poster. I thought you were attempting to hijack the discussion with your reply to Sports' post. Sorry. Speaking of late breaking posters accepted by the ADA, did you know that according to Dr. Kendall they only accept approx. 10% of those late breaking submissiions, which to me says they were impressed enough by the reduced hypo's when compared to aspart numbers that they thought it was 90% more important then the other submissions.
|
|
|
Post by joeypotsandpans on May 22, 2018 14:44:18 GMT -5
IMO, nothing will have a more significant impact than Dr. Kendall's new Scientific Advisory Board combined with fresh new articles written by him and published in major medical journals, explaining the simplicity and superior results of Afrezza (STAT). The company has not been able to do this previously. As diabetes industry leaders become aware of and start discussing the results that Mike says, "doctors can't believe", then the ADA, insurance coverage, marketing expansions, scripts and another label improvement will all begin falling into place. I'll let MN edit the countries and or studies, but to your point the first 2 country domino's got flicked (Brazil & India) by MNKD's version of Curry, the study domino is about to get flicked by their version of LeBron, unfortunately the inaugural team was akin to the Raptors (especially after they lost their illustrious owner)...looks good until they get to the playoffs, time to take it to the next level. Kastanes stop worrying about the runway they (the doubters and hecklers) have been preaching the worrying about it for years....thoughts of selling the golden goose off before it starts laying the eggs is why bus drivers will always drive the bus and not own the bus company
|
|
|
Post by joeypotsandpans on May 21, 2018 13:02:18 GMT -5
Come on... even with the most amazing product launch you have to tilt the hockey stick as if a player is holding it Though if we hit that 5000 script week Mike was talking about tomorrow... repost this. Is this better?
I had to bump this as I find it most appropriate today, especially after reading the following....boy are they in for a rude awakening (see below) IMO. This tells me how far from reality they currently are with the sequence of events that have transpired over the last 3 mos. ......the capacity utilization will be taken care of via the deals that the company is making ala Cipla...in essence MNKD will be it's own contract manufacturer for the deals they will keep signing to bring the COGS down....another takeaway from Mike last Tues. Matt_PK Comments (387) |+ Follow The underlying thesis, that Afrezza is not likely to be financially successful enough in the hands of MNKD to create a sustainable enterprise, has considerable merit. As much merit as your suggesting that the company would already be BK at this point in time to some on this board via direct message? (please feel free to deny if you are not the same Matt from proboards) Where you lose me is the suggestion that MNKD focus on drug delivery, particularly Technosphere, AND become a contract manufacturer. To have a credible strategy, and one that is affordable, I suggest the company should pick one or the other. It is true that Danbury has tremendous excess capacity, but is that plant (and its overhead) best left in the hands of MNKD or should it be sold off to one of the numerous contract manufactures that support the pharma industry, most of whom produce huge quantities of drugs and bring more contract manufacturing experience? A change of ownership does not necessarily mean that TS production would no longer be available, just that it would not be the sole source of revenue for the facility. A facility sale would allow the company to pay down the Deerfield debt unless the plant has so little value on the open market that the "mortgage" is further underwater than a Florida condominium. As a drug delivery technology company, MNKD could potentially be more competitive but TS is clearly not positioned to be all things to all people, and the company would need to acquire or develop additional technologies. Absent a broader technology portfolio, the "new" MNKD would be like the proverbial tradesman who, owning only a hammer, wanders around town looking for a nail, but TS could be a critical tool in an expanded toolset to be offered to other pharma companies. However, expanding the toolset would require a shift in philosophy to something akin to a pure R&D shop which implies a different set of management skills and corporate resources. Regardless of which strategy is chosen, having an underutilized plant in the Connecticut and a corporate office in California is not a particularly desirable real estate configuration trying to pivot to a new strategy while limiting the future cash burn. Any change will have to be driven from the board, and that in turn will require some difficult discussions that I am not sure they are ready to have. 21 May 2018, 11:43 AM Reply0Like Spencer Osborne, Contributor Comments (14522) |+ Follow Author’s reply » Matt..... I was contemplating a starting off point. We agree that the plant in CT is underutilized. See above regarding large volume deals internationally to offset excess capacity and inventory until sales ramp up in U.S. which they will just like that Golden Knights hockey stick... It happens to have massive manufacturing capacity with Technosphere. If the company were to structure deals in such a way that it got a royalty and a manufacturing contract, it gives time to build up the value of that plant. Most likely why the deal with Cipla was backend loaded...you are stating things that are already taking place... I agree that there will likely be a "one or the other" moment. At issue is whether they can convince a single player to buy up the technology or whether there is more than one player. No issue, there will be players in their respective geographic regions that will partner with Mannkind doing the manufacturing.... Multiple players makes ownership stay in MannKind's court. Yes this is a correct statement.What we know is that MannKind has not been adept at selling drugs. Nor does it have the resources to give it the best possible effort. The CT facility is essentially tied to Deerfield as collateral, making things even more complicated. This last statement is based on prior mgmt, current mgmt has been in place for a relatively short period of time and is making great strides considering the pieces they were left with when they took over...21 May 2018, 11:59 AM Reply1Like
|
|
|
Post by joeypotsandpans on May 20, 2018 18:51:55 GMT -5
When relative to Arena (Belviq) I get where Spencer is coming from, however, as he states the pipeline right now consists of Afrezza and a phase I possible PAH technosphere treatment. From our gathering last Tues. evening it was clear to me that Mike and the company are 100% focused on the task at hand which is massively increasing the pull side of the equation to get scripts into the hockey stick direction. He stated Trep-T was as black and white as could be as the response they received from the FDA was very clear regarding what would be needed to move it forward and because of that it would be the most sensible next drug to move forward with the least cash drain. With limited resources, as Spencer states they need to be very prudent in threading the needle regarding juggling cash spend in moving a pipeline along while at the same time making sure their pearl/jewel realizes the potential that those believe it has.
One could question although it was a partnership, that had Sanofi actually took the full rights to Afrezza how that would have played out? Do you think MNKD would have been receiving a windfall of royalties by now, personally I doubt it? So regarding the idea of creating a "new Mannkind" and analogizing it to ARNA all things considered it would be safe to say that Belviq was not necessarily threatening a huge direct disruption to specific BP franchises per se ie., NOVO, LLY, SNY, MRK among others. So having said that, I believe there would be an inherent risk associated with giving up the rights to Afrezza, especially to one of the larger companies already in the space that could do what Al had feared if in the wrong hands, and that would be the self-serving interest of burying to preserve the status quo of diabetes care. It would be nice to assume that the BP's would do the noble thing, however we all know what happens when we assume, especially when it comes to bottom lines.
I'm on board with the fact that the label change was not quite what MNKD was looking for. I believe they wanted it in a separate class to distinguish the benefits and helping create the ability to enter as a new class of insulin that would become a Tier 2 on formulary for speed of response and reduced hypo risk...as others have mentioned, that was not possible due to the way the studies were instructed by the FDA and designed and followed by MNKD. However, I believe Spencer is lumping the STAT study and the late breaking submission regarding reduced hypo risk in with the updated label results. After listening to Dr. Kendall regarding both the STAT along with the accepted late breaking study on reduced hypos and what their impact will be on the providers, I am in agreement that it will result in a sharp increasse in pull through from the providers and lead to increased better coverage insurance wise. This is where I see Mike being confident in reaffirming guidance.
|
|
|
Post by joeypotsandpans on May 20, 2018 12:56:52 GMT -5
Barnstormer, i am copying your question from the scripts section here as this may help direct specific questions to Spencer from others and keep it in one thread and out of the new member introduction thread. Hope this helps. barnstormer Researcher *** barnstormer Avatar Die Hard Biotech Investor Posts: 91Male Sentiment: Long Symphony Script Data 4 hours ago sportsrancho, centralcoastinvestor, and 2 more like this ReplyQuote like Post Options Post by barnstormer on 4 hours ago When is Spencer going to address the fact that if a patient gets a 90 day supply the scrip numbers are skewed as a 3 month supply should = 3 scrips based on Symphony data.
Read more: mnkd.proboards.com/thread/2679/symphony-script-data?page=245#ixzz5G484UR65
|
|
|
Post by joeypotsandpans on May 18, 2018 14:00:51 GMT -5
Dr. Kendall from ASM: " A T A, awareness, trial, adoption", that is his mantra. Regarding awareness - the studies translated to the providers, the SAB leadership acknowledging the benefits/advantages of using the lungs as opposed to the fears...changing the current mindset tactically via a few different fronts, was a very powerful message he put forth on a designed plan and fairly quickly. Regarding trials, this is with respect to getting the providers to understand the effective dosing and the PK/PD profile advantages over his (other strong quote) "the ancient, barbaric and unpredictable current Raa's", and finally regarding adoption via successful pull through from the previous two steps to Afrezza's success including high retention from proven results. He holds himself extremely accountable and exuded confidence to be able to accomplish this as his main objective going forward and has already made significant strides in just 13 weeks. The read I got from him was like a player that gets traded from a team with no shot to one that is a playoff contender and they say this is fun again...sitting there you could easily sense visually and audibly the sincerity of his excitement. Now THIS is interesting news, JPAP. Didn't Kendall mention at a recent investors conference that he was digging into the CT-Scan (Lung) data from the Afresa/Afrezza clinical trials? Perhaps there's some data in there that will help Afrezza on any lung safety concerns?
Yes this stood out to me, I also caught the tail end of a statement regarding his familiarization with Afrezza from his being part of one of the studies regarding the Medtone inhaler, perhaps one of the others remember the full context of it and what it was in reference to, he was going a mile a minute with various topics. Also, in a conversation i was having at the restaurant with CCO Pat M. he was telling me how this reminded him of when he was at Astellas and the launch of Myrbetriq vs. the then current treatments and how they were the little guy about to take on the larger players and it would be a tough road....they ended up becoming a huge player in the space. Again, night and day with this mgmt. team that has been put together by Mike, not meant in a disrespectful way just stating the facts.
|
|
|
Post by joeypotsandpans on May 18, 2018 12:32:50 GMT -5
Get 100 doctors to prescribe to al least 20 of their patients... Doctor K, start calling. Dr. Kendall from ASM: " A T A, awareness, trial, adoption", that is his mantra. Regarding awareness - the studies translated to the providers, the SAB leadership acknowledging the benefits/advantages of using the lungs as opposed to the fears...changing the current mindset tactically via a few different fronts, was a very powerful message he put forth on a designed plan and fairly quickly. Regarding trials, this is with respect to getting the providers to understand the effective dosing and the PK/PD profile advantages over his (other strong quote) "the ancient, barbaric and unpredictable current Raa's", and finally regarding adoption via successful pull through from the previous two steps to Afrezza's success including high retention from proven results. He holds himself extremely accountable and exuded confidence to be able to accomplish this as his main objective going forward and has already made significant strides in just 13 weeks. The read I got from him was like a player that gets traded from a team with no shot to one that is a playoff contender and they say this is fun again...sitting there you could easily sense visually and audibly the sincerity of his excitement.
|
|
|
Post by joeypotsandpans on May 18, 2018 11:38:58 GMT -5
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 27th ANNUAL SCIENTIFIC & CLINICAL CONGRESS Boston, MA • May 16-20, 2018
Booth 1524 - Sanofi / Sanofi Regeneron Booth 1417 - MannKind Corporation Booth Booth 1409 - Novo Nordisk - Diabetes Care
www.eventscribe.com/2018/AACE/exhibitors/
This location should be getting some good foot traffic this week, IMO:
Again what stands out to me is the little booth way in the corner in the other room.....booth 132, is it me or does it look like LLY stands ashamed in the corner of the room for having lost some key personnel? Bioexec what say ye?
|
|
|
Post by joeypotsandpans on May 17, 2018 21:46:18 GMT -5
It may be way early to expect a big jump in scripts already tomorrow based on the remarkable annual shareholders meeting. As the executive team executes its plan, however, I think the CEO's remark about wanting 5,000 scripts per week will come to fruition. Afrezza sales may soon be approaching the heal of the hockey stick. Sorry, just couldn't help myself
|
|
|
Post by joeypotsandpans on May 17, 2018 14:56:16 GMT -5
Speaking of ASM's I have come to understand by not just one shareholder from this forum that also a certain "respected" member of this very board (the same forum that has been referred to as an "echo chamber" by one particular "writer" lol) actually solicited via direct messaging these shareholders to sell their shares predicting a BK TWO YEARS AGO!! Whilst talking/conspiring about the possibility of raising funds to take advantage of same projected sequence of events. Nothing surprises me anymore surrounding the failure of the dark side that continues to try and lean against this little engine that could story. You can't make this stuff up. Liane, feel free to private message me if need be regarding same. So name the name(s). Anyway, be that as it may, it is the case that selling shares two years ago would have been a fairly profitable trade. He acknowledged them at the meeting as they were interspersed among the other staff that was in attendance and it was rather spontaneous, maybe one of the others was able to catch their complete names or if it was recorded or on video maybe you and some others can get creative and have a field day with it. lol. Regarding the aspects of your other statement, you miss the entire point of the post of someone soliciting/targeting individuals to sell their shares and the intended purposes thereof. Perhaps some of those that were on the receiving end wish to respond, that would be up to them.
|
|
|
Post by joeypotsandpans on May 17, 2018 14:33:34 GMT -5
You know it was no coincidence. Just tiring - orchestrated and obnoxious. Nothing will stop it - just freedom of speech, no matter how ignorant or arrogant some of us find it. IMO, it would help to have someone on the 'bull' side of things respond to these constant daggers. At least, someone on the opposite side or more in the middle would certainly be refreshing. Who knows, maybe that will happen soon. It is selective freedom of speech, I have decided to stop the back and forth between the boards and will not corrupt this board (it has already picked up a fair amount of "rifraf" along with their attempts at distracting and smoke screening) and take it down to his level, he is free to respond here directly so we can have a respectful dialogue which I would actually prefer but he feels like he is "above" this board which in and of itself says a lot about him IMO. However, you can memorialize the analysis and comments made by him and others and bring them up down the road to illustrate just how ridiculous they originally were. At this point, having read where their thesis is especially regarding their opinion of selling Afrezza off to "save the company" it is obvious they just don't get it (cannot be fixed so to speak) that it is Afrezza that is ultimately the pearl in this oyster and it's success along with potentially now (Trep-T) validates Technosphere, if you sell the pearl (Afrezza), it just leaves the oyster shell.
|
|